Literature DB >> 32250320

Associations of Lower Caffeine Intake and Plasma Urate Levels with Idiopathic Parkinson's Disease in the Harvard Biomarkers Study.

Rachit Bakshi1,2, Eric A Macklin2,3, Albert Y Hung1,2, Michael T Hayes2,4, Bradley T Hyman1,2, Anne-Marie Wills1,2, Stephen N Gomperts1,2, John H Growdon1,2, Alberto Ascherio3, Clemens R Scherzer1,2,4,5, Michael A Schwarzschild1,2.   

Abstract

Two purines, caffeine and urate, have been associated with a reduced risk of idiopathic Parkinson's disease (PD) in multiple cohorts and populations. The Harvard Biomarkers Study (HBS) is a longitudinal study designed to accelerate the discovery and validation of molecular diagnostic and progression markers of early-stage PD. To investigate whether these 'reduced risk' factors are associated with PD within this cohort, we conducted a cross-sectional, case-control study in 566 subjects consisting of idiopathic PD patients and healthy controls. Caffeine intake as assessed by a validated questionnaire was significantly lower in idiopathic PD patients compared to healthy controls in males (mean difference -125 mg/day, p < 0.001) but not in females (mean difference -30 mg/day, p = 0.29). A strong inverse association was also observed with plasma urate levels both in males (mean difference -0.46 mg/dL, p = 0.017) and females (mean difference -0.45 mg/dL, p = 0.001). Both analyses stratified for sex and adjusted for age, body mass index, and either urate level or caffeine consumption, respectively. These results highlight the robustness of caffeine intake and urate as factors inversely associated with idiopathic PD.

Entities:  

Keywords:  Caffeine; Parkinson’s disease; biomarker; uric acid

Mesh:

Substances:

Year:  2020        PMID: 32250320      PMCID: PMC7416447          DOI: 10.3233/JPD-191882

Source DB:  PubMed          Journal:  J Parkinsons Dis        ISSN: 1877-7171            Impact factor:   5.568


  17 in total

1.  PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease.

Authors:  Bin Zheng; Zhixiang Liao; Joseph J Locascio; Kristen A Lesniak; Sarah S Roderick; Marla L Watt; Aron C Eklund; Yanli Zhang-James; Peter D Kim; Michael A Hauser; Edna Grünblatt; Linda B Moran; Silvia A Mandel; Peter Riederer; Renee M Miller; Howard J Federoff; Ullrich Wüllner; Spyridon Papapetropoulos; Moussa B Youdim; Ippolita Cantuti-Castelvetri; Anne B Young; Jeffery M Vance; Richard L Davis; John C Hedreen; Charles H Adler; Thomas G Beach; Manuel B Graeber; Frank A Middleton; Jean-Christophe Rochet; Clemens R Scherzer
Journal:  Sci Transl Med       Date:  2010-10-06       Impact factor: 17.956

2.  Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study.

Authors:  Hongliu Ding; Alison K Sarokhan; Sarah S Roderick; Rachit Bakshi; Nancy E Maher; Paymon Ashourian; Caroline G Kan; Sunny Chang; Andrea Santarlasci; Kyleen E Swords; Bernard M Ravina; Michael T Hayes; U Shivraj Sohur; Anne-Marie Wills; Alice W Flaherty; Vivek K Unni; Albert Y Hung; Dennis J Selkoe; Michael A Schwarzschild; Michael G Schlossmacher; Lewis R Sudarsky; John H Growdon; Adrian J Ivinson; Bradley T Hyman; Clemens R Scherzer
Journal:  Mov Disord       Date:  2011-09-23       Impact factor: 10.338

Review 3.  Environment, lifestyle, and Parkinson's disease: Implications for prevention in the next decade.

Authors:  Connie Marras; Colleen G Canning; Samuel M Goldman
Journal:  Mov Disord       Date:  2019-05-15       Impact factor: 10.338

Review 4.  The epidemiology of Parkinson's disease: risk factors and prevention.

Authors:  Alberto Ascherio; Michael A Schwarzschild
Journal:  Lancet Neurol       Date:  2016-10-11       Impact factor: 44.182

5.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Authors:  A Ascherio; S M Zhang; M A Hernán; I Kawachi; G A Colditz; F E Speizer; W C Willett
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

Review 6.  Parkinson's disease: evidence for environmental risk factors.

Authors:  Karl Kieburtz; Kathryn B Wunderle
Journal:  Mov Disord       Date:  2012-10-24       Impact factor: 10.338

7.  Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Authors:  Joseph J Locascio; Shirley Eberly; Zhixiang Liao; Ganqiang Liu; Ashley N Hoesing; Karen Duong; Ana Trisini-Lipsanopoulos; Kaltra Dhima; Albert Y Hung; Alice W Flaherty; Michael A Schwarzschild; Michael T Hayes; Anne-Marie Wills; U Shivraj Sohur; Nicte I Mejia; Dennis J Selkoe; David Oakes; Ira Shoulson; Xianjun Dong; Ken Marek; Bin Zheng; Adrian Ivinson; Bradley T Hyman; John H Growdon; Lewis R Sudarsky; Michael G Schlossmacher; Bernard Ravina; Clemens R Scherzer
Journal:  Brain       Date:  2015-07-28       Impact factor: 13.501

8.  Cautionary optimism: caffeine and Parkinson's disease risk.

Authors:  Leonard L Sokol; Michael J Young; Alberto J Espay; Ronald B Postuma
Journal:  J Clin Mov Disord       Date:  2016-06-06

9.  Specifically neuropathic Gaucher's mutations accelerate cognitive decline in Parkinson's.

Authors:  Ganqiang Liu; Brendon Boot; Joseph J Locascio; Iris E Jansen; Sophie Winder-Rhodes; Shirley Eberly; Alexis Elbaz; Alexis Brice; Bernard Ravina; Jacobus J van Hilten; Florence Cormier-Dequaire; Jean-Christophe Corvol; Roger A Barker; Peter Heutink; Johan Marinus; Caroline H Williams-Gray; Clemens R Scherzer
Journal:  Ann Neurol       Date:  2016-11       Impact factor: 10.422

10.  Enhancers active in dopamine neurons are a primary link between genetic variation and neuropsychiatric disease.

Authors:  Xianjun Dong; Zhixiang Liao; David Gritsch; Yavor Hadzhiev; Yunfei Bai; Joseph J Locascio; Boris Guennewig; Ganqiang Liu; Cornelis Blauwendraat; Tao Wang; Charles H Adler; John C Hedreen; Richard L M Faull; Matthew P Frosch; Peter T Nelson; Patrizia Rizzu; Antony A Cooper; Peter Heutink; Thomas G Beach; John S Mattick; Ferenc Müller; Clemens R Scherzer
Journal:  Nat Neurosci       Date:  2018-09-17       Impact factor: 24.884

View more
  7 in total

1.  Cognition, motor symptoms, and glycolipid metabolism in Parkinson's disease with depressive symptoms.

Authors:  Cong Yao; Lichao Niu; Yun Fu; Xu Zhu; Junfeng Yang; Peng Zhao; Xiaoxiao Sun; Yanyan Ma; Shen Li; Jie Li
Journal:  J Neural Transm (Vienna)       Date:  2021-11-27       Impact factor: 3.850

Review 2.  Do caffeine and more selective adenosine A2A receptor antagonists protect against dopaminergic neurodegeneration in Parkinson's disease?

Authors:  Jiang-Fan Chen; Michael A Schwarzschild
Journal:  Parkinsonism Relat Disord       Date:  2020-12-19       Impact factor: 4.891

Review 3.  Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease.

Authors:  Giovanni Schepici; Serena Silvestro; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-07-04       Impact factor: 5.923

4.  Aquatic exercise associated or not with grape juice consumption-modulated oxidative parameters in Parkinson disease patients: A randomized intervention study.

Authors:  Grazielle S De Oliveira; Gislaine S Pinheiro; Isabel C T Proença; Amanda Blembeel; Marcela Z Casal; Daniela Pochmann; Leonardo Tartaruga; Flavia G Martinez; Alex Sander Araújo; Viviane Elsner; Caroline Dani
Journal:  Heliyon       Date:  2021-02-05

Review 5.  Methylxanthines and Neurodegenerative Diseases: An Update.

Authors:  Daniel Janitschke; Anna A Lauer; Cornel M Bachmann; Heike S Grimm; Tobias Hartmann; Marcus O W Grimm
Journal:  Nutrients       Date:  2021-02-28       Impact factor: 5.717

Review 6.  The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease.

Authors:  Akihisa Mori; Jiang-Fan Chen; Shinichi Uchida; Cecile Durlach; Shelby M King; Peter Jenner
Journal:  Molecules       Date:  2022-04-06       Impact factor: 4.411

Review 7.  Life style and Parkinson's disease.

Authors:  Heinz Reichmann; Ilona Csoti; Jiri Koschel; Stefan Lorenzl; Christoph Schrader; Juergen Winkler; Ullrich Wüllner
Journal:  J Neural Transm (Vienna)       Date:  2022-05-23       Impact factor: 3.850

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.